Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05860374

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Sponsor: Shanghai Yunying Medical Technology

Conditions Breast Cancer Carcinoma Colorectal Cancer Gastric Cancer Gynecologic Cancer Liver Cancer Lung Cancer Pancreatic Cancer Sarcoma

Interventions Recombinant oncolytic herpes simplex virus type 1 (R130)

Updated 4 times since 2023 Last updated: May 8, 2023 Started: Mar 2, 2023 Primary completion: Mar 2, 2025 Completion: Mar 2, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Breast Cancer and Carcinoma and is currently ongoing. Shanghai Yunying Medical Technology leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Unknown EARLY_PHASE1

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jun 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Yunying Medical Technology
The Affiliated Hospital of Xuzhou Medical University

Data source: Shanghai Yunying Medical Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China